Trial Profile
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 19-May-2014), according to European Clinical Trials Database record.
- 18 Nov 2013 Status changed from recruiting to discontinued, according to a Sanofi media release. Development of fedratinib has been discontinued.
- 09 Jan 2013 The number of treatment arms changed from 3 to 4. Now the treatment arm consist of an extra arm of 600 mg.